Lisdexamfetamine

How do stimulants actually work to reduce ADHD symptoms?

Retrieved on: 
금요일, 10월 27, 2023

Stimulants are first-line drugs for children and adults diagnosed with attention-deficit hyperactivity disorder (ADHD). But how do they actually work?First, let’s look at the brainMedical imaging indicates people with ADHD may have slight differences in their brain’s structure, the way their brain regions work together to perform tasks, and how their brain’s chemical messengers, called neurotransmitters, pass on information.

Key Points: 


Stimulants are first-line drugs for children and adults diagnosed with attention-deficit hyperactivity disorder (ADHD). But how do they actually work?

First, let’s look at the brain

  • Medical imaging indicates people with ADHD may have slight differences in their brain’s structure, the way their brain regions work together to perform tasks, and how their brain’s chemical messengers, called neurotransmitters, pass on information.
  • These brain differences are associated with the symptoms of ADHD, including inattention, impulse control and problems with memory.

What stimulants are prescribed in Australia?

  • The three main stimulants prescribed for ADHD in Australia are dexamfetamine, methylphenidate (sold under the brand names Ritalin and Concerta) and lisdexamfetamine (sold as Vyvanse).
  • Dexamfetamine and methylphenidate have been around since the 1930s and 1940s respectively.

So how do they work for ADHD?

  • Stimulants increase the amount of dopamine and noradrenaline in the tiny gaps between neurons, known as synapses.
  • They do this by predominantly blocking a transporter that then prevents their re-uptake back into the neuron that released them.
  • Amphetamines also increase the amount of dopamine the neuron releases into the synapse (the tiny gaps between neurons).

What effect do they have on ADHD symptoms?


We still don’t fully understand the underlying brain mechanisms that change behaviour in people with ADHD. But research shows stimulants that modulate noradrenaline and dopamine can improve brain processes such as:
They can also improve general behaviour, such as self-control, not talking over the top of others, and concentration. These behaviours are important for social interactions. Stimulants reduce ADHD symptoms in about 70% to 80% of children and adults who take them. Some people will notice their symptoms improve right away. Other times, these improvements will be more noticeable to parents, carers, teachers, colleagues and partners.

Not everyone gets the same dose


The optimal stimulant dose varies between individuals, with multiple dosage options available. This enables a “start low, go slow” approach, where the stimulant can be gradually increased to the most effective dose for the individual.

  • Dexamfetamine and methylphenidate are available in immediate-release preparations.
  • As these have short half-lives (meaning they act quickly and wear off rapidly), they are often taken multiple times a day – usually in the morning, lunch and afternoon.
  • Methylphenidate is also available in long-acting tablets (Concerta) and capsules (Ritalin LA).

What are the side effects?


The most common side effects are sleep problems and decreased appetite. A recent study showed children and young people taking methylphenidate for ADHD were around 2.6 times more likely to have sleep problems and 15 times more likely to have a decreased appetite than those not taking methylphenidate. Headache and abdominal pain are also relatively common.

Can someone without ADHD take a stimulant to improve productivity?

  • As stimulants increase dopamine, they can cause euphoria and a heightened sense of wellbeing.
  • A common myth about stimulant medicines is they can improve the concentration and productivity of people without ADHD.
  • At each of the sessions, participants were given either a placebo or a stimulant before completing the task.
  • Read more:
    ADHD medications have doubled in the last decade – but other treatments can help too


Mary Bushell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
목요일, 10월 19, 2023

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
목요일, 10월 19, 2023

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

 Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

Retrieved on: 
수요일, 9월 6, 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
    Lisdexamfetamine dimesylate capsules is a generic version of Vyvanse®.
  • This ADHD product is currently on the U.S. FDA shortage product list, and Amneal has already begun supplying product to the market.
  • Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and above and for adults with moderate to severe Binge Eating Disorder.
  • According to IQVIA®, U.S. annual sales for lisdexamfetamine dimesylate for the 12 months ended June 2023 were $5.3 billion.

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Retrieved on: 
목요일, 8월 31, 2023

The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyvanse® Capsules of Takeda Pharmaceuticals U.S.A., Inc. (Takeda), in all seven of the RLD's approved strengths.

Key Points: 
  • The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyvanse® Capsules of Takeda Pharmaceuticals U.S.A., Inc. (Takeda), in all seven of the RLD's approved strengths.
  • Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.
  • Global net sales of Lisdexamfetamine Dimesylate exceeded $3.0 billion in Takeda's fiscal year ended March 31, 2023.
  • Upon receiving approval, which came the day following the expiration of the RLD's pediatric exclusivity, Mallinckrodt began immediate commercialization of the product.

LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Featuring Eli Lilly, Pfizer, Johnson & Johnson, Novartis & More - ResearchAndMarkets.com

Retrieved on: 
수요일, 1월 11, 2023

Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.

Key Points: 
  • Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.
  • This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation.
  • The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028.
  • Additionally, The UAE market would register a CAGR of 7% during (2022-2028).

Haug Partners Successfully Defends Takeda’s Vyvanse® Patents At Trial Against Generic Challenge

Retrieved on: 
수요일, 12월 28, 2022

Judge Chesler held that all of Takeda’s asserted patents were infringed, not invalid under 35 U.S.C.

Key Points: 
  • Judge Chesler held that all of Takeda’s asserted patents were infringed, not invalid under 35 U.S.C.
  • As a result, Judge Chesler enjoined Defendant Norwich from bringing its generic product to market until August 24, 2023, upon expiration of Takeda’s Pediatric Exclusivity period for Vyvanse®.
  • The trial focused on fourteen claims asserted across nine Orange Book-listed patents.
  • The Court also afforded significant weight to admissions by Norwich’s Rule 30(b)(6) witnesses elicited during depositions and played at trial.

TELUS Health releases annual Health Drug Data Trends Report 2022: Pandemic side effects include rise in medications for depression and ADHD

Retrieved on: 
수요일, 6월 22, 2022

The report shows a noticeable increase in ADHD medication and antidepressants in 2021.

Key Points: 
  • The report shows a noticeable increase in ADHD medication and antidepressants in 2021.
  • With work-from-home and hybrid workstyles now the norm, it is clear that the pandemic created unique challenges for Canadians, impacting both their mental and physical health, said Shawn OBrien, Principal, Data Enablement and HBM Product, TELUS Health.
  • Five years ago, medications like Vyvanse and Concerta, used to treat neurodivergent-related disorders such as ADHD and narcolepsy, ranked 10th, while in 2021, these medications surpassed cancer medications.
  • TELUS Health is a leader in digital health technology, providing virtual care, home health monitoring, electronic medical and health records, benefits and pharmacy management, and personal emergency response services.

Vyvanse - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
화요일, 3월 12, 2019

The "Vyvanse - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vyvanse - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Vyvanse Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • A review of the Vyvanse, based on information derived from company and industry-specific sources
    Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification